Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology

被引：10
作者：
Kaimakliotis, Hristos Z. [1 ]
Monn, M. Francesca [1 ]
Cho, Jane S. [1 ]
Pedrosa, Jose A. [1 ]
Hahn, Noah M. [2 ]
Albany, Costantine [3 ]
Gellhaus, Paul T. [1 ]
Cary, K. Clint [1 ]
Masterson, Timothy A. [1 ]
Foster, Richard S. [1 ]
Bihrle, Richard [1 ]
Cheng, Liang [3 ]
Koch, Michael O. [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Urol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
[2] Johns Hopkins Sch Med, Dept Genitourinary Med Oncol, 1550 Orleans St,Room 1M51, Baltimore, MD 21287 USA
[3] Indiana Univ Sch Med, Dept Genitourinary Med Oncol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 15期
关键词：
GEMCITABINE PLUS CISPLATIN; RADICAL CYSTECTOMY; POOR-PROGNOSIS; PHASE-III; CARCINOMA; METHOTREXATE; VINBLASTINE; DOXORUBICIN; SURVIVAL; METAANALYSIS;
D O I：
10.2217/fon-2016-0056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.
引用
收藏
页码：1795 / 1804
页数：10
相关论文
共 50 条
  • [41] Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
    Marcq, Gautier
    Jarry, Edouard
    Ouzaid, Idir
    Hermieu, Jean-Francois
    Henon, Francois
    Fantoni, Jean-Christophe
    Xylinas, Evanguelos
    THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 8
  • [42] Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Toh, Chee-Keong
    Kanesvaran, Ravindran
    Ng, Quan Sing
    Tan, Min-Han
    Tan, Yew Oo
    Tay, Miah Hiang
    Wong, Alvin
    Tan, Hui Shan
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2015, 44 (10) : 415 - 420
  • [43] Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer
    Liew, Mun Sem
    Au-Yeung, George
    Davis, Ian D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 101 - 102
  • [44] Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
    O'Donnell, Peter H.
    Alanee, Shaheen
    Stratton, Kelly L.
    Garcia-Grossman, Ilana R.
    Cao, Hongyuan
    Ostrovnaya, Irina
    Plimack, Elizabeth R.
    Manschreck, Christopher
    Ganshert, Cory
    Smith, Norm D.
    Steinberg, Gary D.
    Vijai, Joseph
    Offit, Kenneth
    Stadler, Walter M.
    Bajorin, Dean F.
    CLINICAL GENITOURINARY CANCER, 2016, 14 (06) : 511 - 517
  • [45] Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology
    Lin, James
    Whalen, Michael
    Holder, Dara
    Hruby, Gregory
    DeCastro, G. Joel
    McKiernan, James
    CANADIAN JOURNAL OF UROLOGY, 2013, 20 (02) : 6690 - 6695
  • [46] The Natural History of Clinically Complete Responders to Neoadjuvant Chemotherapy for Urothelial Carcinoma of the Bladder
    Meyer, Alexa
    Ghandour, Rashed
    Bergman, Ari
    Castaneda, Crystal
    Wosnitzer, Matthew
    Hruby, Greg
    Benson, Mitchell
    Mc Kiernan, James
    JOURNAL OF UROLOGY, 2014, 192 (03) : 696 - 701
  • [47] The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?
    Monn, M. Francesca
    Kaimakliotis, Hristos Z.
    Cary, K. Clint
    Bihrle, Richard
    Pedrosa, Jose A.
    Masterson, Timothy A.
    Foster, Richard S.
    Gardner, Thomas A.
    Cheng, Liang
    Koch, Michael O.
    BJU INTERNATIONAL, 2015, 116 (02) : 236 - 240
  • [48] Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    Salminen, Antti P.
    Perez, Ileana Montoya
    Klen, Riku
    Ettala, Otto O.
    Syvanen, Kari T.
    Elo, Laura L.
    Bostrom, Peter J.
    BLADDER CANCER, 2019, 5 (04) : 273 - 279
  • [49] Lack of Pathologic Down-Staging With Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder
    Weight, Christopher J.
    Garcia, Jorge A.
    Hansel, Donna E.
    Fergany, Amr F.
    Campbell, Steven C.
    Gong, Michael C.
    Jones, J. Stephen
    Klein, Eric A.
    Dreicer, Robert
    Stephenson, Andrew J.
    CANCER, 2009, 115 (04) : 792 - 799
  • [50] Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity
    Johnson, David C.
    Nielsen, Matthew E.
    Matthews, Jonathan
    Woods, Michael E.
    Wallen, Eric M.
    Pruthi, Raj S.
    Milowsky, Matthew I.
    Smith, Angela B.
    BJU INTERNATIONAL, 2014, 114 (02) : 221 - 228
12345